Gold‐lutetium‐177 nanoparticles were likewise considered by Reilly's group as an alternative neoadjuvant regimen to treat human epidermal growth factor receptor‐2 (HER2) positive breast cancer.[31] Trastuzumab, a therapeutic monoclonal antibody targeting HER2, was associated, as above, in a hybrid nanoconstruct together with 177Lu and gold nanoparticles. The gene discussed is ERBB2; the disease is breast carcinoma.